NYU Langone Health
The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH. The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).
Inclusion Criteria: Provider Eligibility Criteria (Phase 1) * Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics, * Provide care to at least 5 patients prescribed an IMM. Patient Eligibility Criteria (Phase 1) * (Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months; * Fluency in English or Spanish; * Be willing to send/receive text messages; and * Be \> 18 years of age. Exclusion Criteria: Provider Exclusion Criteria (Phase 1) • Refuse to participate Patient Exclusion Criteria (Phase 1) • Refuse or are unable to provide in…
GenAI-powered CDS tool that provides a range of IMM management services, such as personalized guidance for patients on side effects management and clinical advisement to optimize dose titrations.
Arctuva estimate
Verify or correct the compensation shown for this listing.